Alnylam

790 Memorial Drive,
Suite 202,
Cambridge,
MA 02139

United States of America
Tel: 617-252-0700
Fax: 617-252-0011

Alnylam Pharmaceuticals is an early-stage therapeutics company. Founded on the discovery of RNA interference, we are developing technology that can specifically and potently silence disease-causing genes.

Further Information: http://www.alnylam.com/company.html

Related news from our archive

Alnylam Presents Pre-Clinical Data on ALN-TTR for the Treatment of Transthyretin-Mediated Amyloidosis
New data demonstrate durable in vivo efficacy for ALN-TTR at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.

Alnylam Grants KOKEN License to Kreutzer-Limmer Patents for the RNAi Research Products Market
The non-exclusive worldwide license enables KOKEN to manufacture and provide RNAi research products and services under the Kreutzer-Limmer patent family.

Alnylam Announces Allowance in Europe of New Fundamental Patent Broadly Covering RNAi Therapeutics in Oncology
Notification of “Intent to Grant” awarded by European Patent Office for Kreutzer-Limmer III Patent owned by Alnylam.

Alnylam and Tekmira Participate in new Research Collaboration
Collaboration focuses on the discovery of novel cationic lipids and lipid nanoparticles for the systemic delivery of RNAi therapeutics.